Skip to content

Liver cancer has a more aggressive disease course in HIV-positive people co-infected with viral hepatitis

Traditional risk factors strongest predictors of sub-clinical cardiovascular disease in people about to start HIV therapy

HIV and hepatitis C co-infection increases the risk of cognitive impairment

Brivanib fails to match sorafenib for liver cancer, but tivantinib looks promising

Philip Johnson from the University of Birmingham.  © Liz Highleyman / hivandhepatitis.com

FDA Advisory Committee recommends accelerated approval of bedaquiline for drug-resistant TB

HIV and TB in Practice for nurses: Starting ART for treatment and prevention in people with active TB and HIV

Nucleoside analogues reduce hepatitis B liver cancer risk

Dutch find low bone mineral density in gay men, regardless of HIV infection status

Life expectancy in older people with HIV could exceed the average – as long as ART keeps working